Supersaturated Oxygen (SSO2) Therapy in STEMI Treatments

Published: 06 December 2021

  • Views:

    Views Icon 9208
  • Likes:

    Heart Icon 7
  • episode_image
    3m 38s
    Part 4 | Session 1 Introduction
    Sandeep Nathan, Dan Burkhoff, Jerry D Estep, Marat Fudim, Michael Lim, Suzanne J Baron
  • episode_image
    11m 1s
    Part 4 | Session 2 Heart Failure Epidemic in STEMI
    Marat Fudim
  • episode_image
    45m 2s
    Part 4 | Session 3 Fireside Chat
    Sandeep Nathan, Dan Burkhoff, Jerry D Estep, Marat Fudim, Michael Lim, Suzanne J Baron
Average (ratings)
No ratings
Your rating


Despite advances in reperfusion with primary stenting, progress in STEMI outcomes has stalled over the past 20 years. With 90% of coronary blood flow in the capillaries, the answer might be in the microvasculature. TherOx SSO2 Therapy is the first FDA approved therapy shown to significantly reduce the infarct size in STEMI patients.


During this series of webinars on Supersaturated Oxygen (SSO2) Therapy, our faculty of renowned international experts will discuss and dissect the mechanisms and data around this promising new therapy for STEMI patients.

This broadcast series is supported by

Key Objectives

  • Understand how SSO2 Therapy works
  • Hear about trends in STEMI treatment
  • Explore the role of microvascular obstruction and infarct size in outcomes
  • Understand the science behind SSO2 Therapy

Target Audience

This series is designed for the entire cardiology community:

  • Interventional Cardiologists
  • Cardiologists
  • Clinical Fellows and Trainees

More from this programme

Part 1

Supersaturated Oxygen Therapy (SSO2): The Next Frontier in STEMI Treatment

Part 2

SSO2 Therapy in STEMI to Reduce Infarct Size: A Conversation with Global Thought Leaders

Learn about this promising new therapy for STEMI patients and hear from global thought leaders, Dr Dan Burkhoff, Dr Steven Yakubov, Dr Andreas Schäfer and Dr Richard Schatz, about their experiences with it.

Part 3

Infarct Size, Microvascular Obstruction and Outcomes in STEMI: An Expert Panel Discussion

Learn about which patients are at greatest risk of microvascular obstruction (MVO) and large infarcts, how we can diagnose MVO and how we can treat MVO and infarct. Moderated by Dr Nadia Sutton, hear global thought leaders Dr Babar Basir, Dr Dan Burkhoff, Dr Suzanne de Waha and Dr Jay Traverse answer these questions.

Part 4

Transforming STEMI Care: Bridging Interventional and Heart Failure Cardiology to Improve Patient Outcomes

This engaging session features the collaborative efforts of interventional and heart failure cardiologists in revolutionizing the management of ST-Elevation Myocardial Infarction (STEMI) and its impact on heart failure. Through a dynamic fireside chat format, our esteemed panelists will explore groundbreaking approaches and advancements that are reshaping STEMI care.

Faculty Biographies

Richard  Schatz

Richard Schatz

Dr Richard Schatz is research director of cardiovascular interventions at the Scripps Heart, Lung, and Vascular Center and director of gene and stem cell therapy. A recognized international expert in interventional cardiology, he has published and lectured extensively. His seminal work in coronary stents spurred a revolution in the treatment of coronary artery disease – more than 2 million of them are placed annually worldwide, with an immeasurable impact on relieving mortality and morbidity, improving patients’ lives, and reducing healthcare costs.

View full profile
Dan Burkhoff

Dan Burkhoff


Dr Dan Burkhoff is currently the Director of Heart Failure, Hemodynamics and MCS Research at Cardiovascular Research Foundation, New York, US. Dr Burkhoff's interest include cardiovascular modeling and ventricular mechanics, cardiovascular monitoring, heart failure, device and pharmacologic treatments for heart failure, including left ventricular assist devices. He is also author of Harvi, an interactive simulation-based application for teaching and researching on ventricular mechanics and hemodynamics.

View full profile
Steven Yakubov

Steven Yakubov


Dr Yakubov is the John H. McConnell Chair of Advanced Structural Heart Disease, System Medial Chief, Advanced Structural Heart Disease of OhioHealth and Medical Director of Cardiovascular Studies for the OhioHealth Research Institute at Riverside Methodist Hospital, Columbus, OhioHe has been involved in numerous clinical trials to advance treatment options for cardiovascular disease and structural heart disease. He is a speaker at several annual major cardiovascular conferences and has numerous publications in major medical journals and book chapters.  He has been instrumental in the development of new technology for the treatment of structural heart disease.


View full profile
Andreas Schäfer

Andreas Schäfer

Deputy Director

Dr Andreas Schäfer currently holds the position of deputy director at Hannover Medical School and specialises in interventional cardiology. Dr Schäfer has been involved in multiple clinical trials and has published extensively in the field of interventional cardiology.  In addition, he regularly speaks at conferences and educational events globally.



View full profile